Peroxisome proliferator-activated receptor-γ coactivator 1-α (PGC1α) is a transcriptional coactivator able to up-regulate mitochondrial biogenesis, respiratory capacity, oxidative phosphorylation, and fatty acid β-oxidation with the final aim of providing a more efficient pathway for aerobic energy production. In the continuously renewed intestinal epithelium, proliferative cells in the crypts migrate along the villus axis and differentiate into mature enterocytes, increasing their respiratory capacity and finally undergoing apoptosis. Here we show that in the intestinal epithelial surface, PGC1α drives mitochondrial biogenesis and respiration in the presence of reduced antioxidant enzyme activities, thus determining the accumulation of reactive oxygen species and fostering the fate of enterocytes toward apoptosis. Combining gain-and loss-offunction genetic approaches in human cells and mouse models of intestinal cancer, we present an intriguing scenario whereby PGC1α regulates enterocyte cell fate and protects against tumorigenesis.
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colon cancer | medical physiology | metabolism | mitochondria | nuclear receptors T he intestinal epithelium is a dynamic microenvironment in which proliferative progenitor cells in the crypt give rise to epithelial cells that differentiate into mature enterocytes while migrating to the intestinal lumen (1) . Current evidences indicate the well-known Wnt/β-catenin pathway (2) as the main force in the regulation of the crypt-villus homeostasis. Under physiological conditions, intestinal epithelial cells, migrating from the crypt to the top of the villus, reduce their proliferative activity and modify their metabolic behavior, becoming competent for apoptosis (1, 3) . When a somatic mutation occurs, some cells are able to escape apoptosis, thus promoting tumor progression (4, 5) .
Peroxisome proliferator-activated receptor-γ coactivator 1-α (PGC1α) is a transcriptional coactivator of genes encoding proteins responsible for the regulation of mitochondrial biogenesis and function (6, 7) . PGC1α participates in biological responses that require the shift from glycolytic to oxidative metabolism, such as thermogenesis in brown adipose tissue (8) , fiber-type switching in skeletal muscle (9) , and fatty acid β-oxidation, along with gluconeogenesis, in the liver (10) . Despite the large amount of information about the role of PGC1α in high energy-demand tissues, nothing has yet been reported about the role of PGC1α in the intestine. Therefore, we sought to explore whether PGC1α may influence the metabolic fate of intestinal epithelial cells.
Here we show that PGC1α is highly expressed on the surface of the intestinal epithelium, where cells accumulate reactive oxygen species (ROS), probably due to the unbalanced ratio between increased respiration and lower activity of the antioxidant enzymes. In contrast, PGC1α is poorly expressed in the crypts, and its expression is reduced in intestinal tumors. In highly glycolytic proliferative colorectal cancer cells, PGC1α overexpression induces a turbo boost of the mitochondrial machinery with ROS accumulation and apoptosis. Intriguingly, mice overexpressing PGC1α in the intestinal epithelium are strongly protected against tumorigenesis, whereas the opposite is observed in PGC1α
−/− mice. Thus, we propose that PGC1α, reinforcing the physiological effect produced by the expansion of mitochondrial population and function in the intestinal epithelium, could be considered a metabolic regulator of intestinal cell fate and a putative powerful tool against intestinal tumor formation.
Results
PGC1α Is Highly Expressed in the Intestinal Epithelium. We first investigated the expression level of PGC1α in the intestine analyzing mRNA transcripts from mice tissues. We found significant PGC1α levels in the entire gastrointestinal tract (Fig. 1A) . Notably, PGC1α is localized in the differentiated enterocytes that belong to the apical compartment of the epithelium. Conversely, PGC1α has only a scattered expression in the proliferative compartment at the bottom of the crypts (Fig. 1B, red arrows) . Intriguingly, PGC1α expressing apical differentiated enterocytes present a higher respiratory capacity, as evaluated via COX activity (Fig. 1C) . In situ measurement of COX activity by histochemical staining is an indication for respiratory capacity (11) (12) (13) . Furthermore, ROS accumulation (Fig. 1D ) has been detected in the same compartment that results in a susceptibility to apoptosis (Fig. 1E) , probably due to low expression of antioxidant enzymes catalase (CAT) and manganese superoxide dismutase (SOD2; Fig. S1 ) (14, 15) .
We then measured its abundance in intestinal tumor samples from mice and familial adenomatous polyposis (FAP) patients. In both cases, intestinal adenomas result from mutational activation of the Wnt pathway (16), most commonly due to the loss of the intestinal tumor suppressor gene Apc (4, (17) (18) (19) . In colon tumor samples from Apc Min/+ mice and FAP patients, mRNA levels of PGC1α and its target, medium-chain acyl-CoA dehydrogenase (MCAD) were 70-90% lower than the mRNA levels of the adjacent intestinal mucosa, similar to the expression pattern of differentiation marker genes such as p21 and Keratin20 (Fig. 1F ).
PGC1α Induces Mitochondrial Proliferation and Activation in Human
Intestinal Cancer Cells. Switching mitochondrial activity is a putative form of cancer therapy (20, 21) . We explored whether PGC1α expression induces metabolic remodeling and/or modifies cell behavior in an undifferentiated and proliferative intestinal tumor cell. Overexpression of PGC1α in HT29 cells markedly activated its transcriptional machinery, as shown by the increase in the expression of several target genes-namely, MCAD, mitochondrial transcription factor A (Tfam), and ATP synthase β-subunit (ATP5B; Fig. 2A ). This gene expression scenario was accompanied by metabolic changes. Indeed, though no changes were observed in the glycolysis rate using H]glucose as a substrate (Fig. 2B) , there was a significant increase in mitochondrial fatty acid β-oxidation, as shown by the [9, H] palmitic acid oxidation rate (Fig. 2C) . We also observed a net expansion of the mitochondrial population, indicated by increased mtDNA molecules and MitoTracker staining (Fig. 2 D and E), followed by an increase in oxygen consumption (Fig. 2F ) calculated on cells without cytochrome c (cyt c) efflux (22) . PGC1α overexpression produced a proapoptotic effect, highlighted by Annexin V staining ( Fig. 2G and Fig. S2A ) and cyt c efflux (Fig. S2B ). Under these conditions, cells decrease their proliferative rate (Fig. S2C) . These data suggest that PGC1α promotes a coordinate metabolic shift toward mitochondrial utilization in proliferative cancer cells.
PGC1α Induces Tissue-Specific ROS Accumulation and Apoptosis. The correct balance between ROS production and the antioxidant systems maintains cellular ROS homeostasis. We thus first measured ROS accumulation after PGC1α overexpression in colorectal cancer cells (HT29 and HCT116) and in nonintestinal cells (143B and C2C12; Fig. 2H ). We observed a very high percentage of ROS-positive cells only in intestinal cancer cells; neither 143B nor C2C12 cells accumulated ROS. The levels of ROS accumulation were completely paralleled by the nucleosome-enrichment observed in the same cells as a sign of apoptosis (23) (Fig.  2I) . In response to PGC1α overexpression, only 143B and C2C12 showed a significant increase in antioxidant enzymes CAT and SOD2 (Fig. S1A ). In tissues with high aerobic energy metabolism, such as brain, heart, skeletal muscle, and brown adipose tissues (6-9, 24, 25) , where PGC1α expression responds to specific stimuli determining the increase in mitochondrial activity, a parallel increase in antioxidant enzyme production (i.e., SOD2 and CAT) occurs to protect cells from oxidative stress. In contrast, colorectal cancer cells did increase their antioxidant defense, thus becoming apoptotic. Our data suggest that the metabolic shift induced by PGC1α in proliferative colorectal cancer cells promotes ROS accumulation and induces apoptosis.
PGC1α Inhibits Intestinal Tumor Growth in a Xenograft Model. Interfering with the glycolytic metabolic scenario of tumor cells can prevent tumor onset and reduce tumor growth (21, 26) . To prove if the proapoptotic PGC1α mitochondrial-driven activity is able to oppose tumorigenesis, we performed a xenograft model in athymic mice using HT29 cells. Adenoviral infection of tumors with PGC1α produced a strong reduction of tumor growth. Indeed, tumors overexpressing PGC1α display a significant delay in their growth compared with mock-treated tumors (Fig. 2J ). Tumors infected with PGC1α presented a net increase in COX staining, indicating activation of mitochondrial respiration (Fig.  2K ). The PGC1α mediated induction of mitochondrial respiration resulted in a net accumulation of ROS with a consequent increase of apoptosis (Fig. 2K ).
PGC1α Proapoptotic Effect Is Lost in HT29ρ0 Cells. To investigate whether the observed ROS boost after PGC1α overexpression was really due to the increased activity of the respiratory chain, we introduced in our study a cellular model that completely lacks mitochondrial DNA (HT29ρ0 cells). This mtDNA-depleted cell line was generated by ethidium bromide treatment (27) . To verify the complete removal of the mtDNA, the total genomic DNA of the HT29ρ0 cells was used as a template in a multiplex PCR test to amplify both the nuclear actin gene and the mtDNA-encoded cytochrome b (cyt b) gene (Fig. 3A) . As shown, the mitochondrial Cytb gene was amplified only in HT29 WT cells. Through Western blot analysis (Fig. 3A) we have also confirmed that the mitochondrial-encoded cyt c oxidase subunit I (COXI) was expressed only in HT29 WT but not in HT29ρ0 cells. To further confirm the bioenergetic functional impact of the mtDNA absence in HT29ρ0 cells, we measured mitochondrial respiratory fluxes in HT29 WT and HT29ρ0 cells (Fig. 3B ). As expected, no antimycin-sensitive oxygen consumption could be detected in intact HT29ρ0 cells in the presence (basal) or in the absence (DNP uncoupled) of the mitochondrial membrane potential. Similarly, no COX activity could be detected in intact HT29ρ0 cells as KCN-sensitive oxygen consumption elicited by the artificial COX-specific electron donors ascorbate + TMPD (Fig. 3B) We then overexpressed PGC1α in both HT29 and HT29ρ0 cells and compared the transcriptional activation of several PGC1α target genes, such as MCAD, Tfam, and ATP5B. As shown in Figs. 2A and 3C, all of these genes are activated in both cell lines, thus Min/+ mice and FAP patients compared with the normal adjacent mucosa. Results are expressed as mean ± SEM. Cyclophilin was used as a reference gene, and values were normalized to data obtained from normal intestinal mucosa (*P < 0.05).
proving that PGC1α transcriptional activity is fully conserved in HT29ρ0 cells. PGC1α promoted significant ROS accumulation in HT29 WT cells but not in HT29ρ0 cells (Fig. 3C) . Moreover, in addition to ROS accumulation, marked nucleosome enrichment also occurred in HT29 WT but not HT29ρ0 cells (Fig. 3C ). These findings support our hypothesis that the proapoptotic effect exerted by PGC1α is tightly related to the increased mitochondrial respiratory chain activity and subsequent intestinal-specific ROS accumulation.
Synthetic SOD2 and Catalase Mimetic EUK134 Abolishes the PGC1α
Proapoptotic Effect. We then studied the effect of PGC1α overexpression in colorectal cancer cells and xenografted tumors in the presence of a synthetic combined catalase and SOD2 mimetic referred to as EUK134 (28) . Treatment of colorectal cancer cells, and of xenografted tumors with EUK134, completely prevented the PGC1α-induced proapoptotic and tumor-suppressor activity. At a molecular level, PGC1α overexpression in the presence of EUK134 did not lead to ROS accumulation and apoptosis (Fig. 3D) . Furthermore, EUK134 prevented a PGC1α-induced reduction in tumor growth rate as well as ROS accumulation and apoptosis in vivo (Fig. 3E) . These data support the model by which the intestinal PGC1α proapoptotic effect depends on the imbalance between increased mitochondrial respiratory capacity and decreased free radical scavenger systems.
PGC1α Stimulates Intestinal Mitochondrial Biogenesis and Respiration in Vivo. To translate the relevance of these effects in the physiological context of the intestinal epithelium, we generated a mouse model in which human PGC1α (hPGC1α) is selectively overexpressed only in the intestinal cells. Thus, by subcloning the hPGC1α coding sequence downstream of the villin promoter, we generated the iPGC1α transgenic mice. These mice express the hPGC1α transgene in the entire length of their intestines (Fig. 4  A and B) . The apical enterocytes of the iPGC1α intestine show an evident increase in the number of mitochondria, as revealed by EM pictures and the percentage of COX-1 staining-positive areas (Fig. 4 C and D) . This constitutive PGC1α expression in the normal intestinal epithelium is thus able to activate mitochondrial biogenesis and activity leading in vivo to ROS accumulation (Fig. 4D) . iPGC1α mice presented a higher number of TUNEL-positive cells surrounding the entire surface of the villi, showing a highly sensitive apoptotic profile if compared with WT mice (Fig. 4D) . The proapoptotic phenotype produced by PGC1α intestinal expression is also reflected by some morphological differences in colon and ileum sections of iPGC1α, PGC1α +/+ , and PGC1α −/− mice. The three different genotypes showed striking differences in the dimension of villi and crypts, which were visibly shorter in iPGC1α mice compared with PGC1α +/+ and, even more, with PGC1α −/− mice ( Fig. S3 and  Fig. S4) . Therefore, higher accumulations of ROS on the surface of iPGC1α intestinal epithelium, if not balanced by antioxidant enzyme activity, induce massive apoptotic events.
Intestinal PGC1α Suppresses Colorectal Carcinogenesis. We next tested the hypothesis that PGC1α might be a unique player in the prevention of intestinal tumorigenesis on two different models of intestinal carcinogenesis. A genetic model of intestinal tumor formation was generated by crossing Apc Min/+ mice (19) with our iPGC1α mice. The second model consisted of a single i.p. injection with azoxymethane (AOM) to initiate cancer by alkylation of DNA facilitating base mispairings (29), followed by three cycles of oral dextran sodium sulfate (DSS) to sustain the intestinal tumor progression via induction of colitis (30) . In the adenomas of iPGC1α/Apc
Min/+ mice that show significant expression of hPGC1α transgene (Fig. 5 A and B) , we observed a higher apoptosis rate compared with tumors of control mice (Fig. 5C) . Indeed, given the reduced SOD staining and mRNA levels in tumors (Fig. S1B) , the PGC1α mediated increase of mitochondrial respiration leads to ROS accumulation. The data obtained in the genetic model proved that the average tumor number and volumes were considerably lower in each intestinal tract (duodenum, jejunum, ileum, and colon) from iPGC1α/ Apc Min/+ mice compared with their littermate controls (Fig. 5 D  and E) , thus confirming that PGC1α protects against intestinal tumorigenesis. Furthermore, in the chemical model, iPGC1α mice presented a significantly lower average tumor number than their littermate controls (Fig. 5F ). Also, though WT mice developed colon tumors with an average volume of 15 mm 
PGC1α
−/− Mice Are Susceptible to Intestinal Tumorigenesis. We then analyzed the effect of PGC1α depletion on the occurrence of intestinal tumors by performing the AOM/DSS protocol on PGC1α +/+ and PGC1α −/− mice. PGC1α −/− mice presented a significantly higher tumor number than their littermate controls (Fig.  5G) . Also, whereas PGC1α +/+ mice developed tumors of an average volume of ∼2 mm 3 in the colon, the tumors in PGC1α −/− mice had an average volume of ∼10 mm 3 . Together, these data strongly support the idea that PGC1α expression levels could influence intestinal epithelial cell fate by inducing mitochondrial-related metabolic modifications that induce apoptosis. Nonetheless, unique antitumoral-specific PGC1α target gene pathways in the intestine could have also contributed to this scenario. Notably, a microarray expression profile analysis performed on intestines of iPGC1α, PGC1α +/+ , and PGC1α −/− mice revealed that no apoptotic-specific pathways appear to be transcriptionally modulated by PGC1α expression levels. Table S1 reports the mRNA expression levels of an array of genes involved in the apoptotic process, along with their fold modification. The gene expression-related pathways susceptible to PGC1α amounts in the mouse intestinal epithelium are therefore entirely involved in cell metabolic control and differentiation, most likely driven by PPAR-γ (31) and estrogen-related receptor-α (32) (Fig. S5 and Table S2 ).
Discussion
This work shows that the nuclear receptor coactivator PGC1α is abundantly expressed in the apical apoptosis-competent compartment of the intestinal epithelium, and that its up-regulation in normal intestinal mucosa and proliferating cancer cells exerts a unique proapoptotic and tumor suppressor role. Several nuclear receptors that interact with PGC1α, such as PPAR-γ (Table S2 ) (33-35), farnesoid X receptors (FXRs) (36) , retinoic acid receptors (RARs), and retinoid X receptors (RXRs) (37), modulate both differentiation and apoptotic pathways in the intestine with a potential pharmacological importance in colon cancer (38) .
Our study started from the consideration that in all of the tissues in which PGC1α is expressed, it increases mitochondrial biogenesis and activity (8) (9) (10) . Thus, we explored whether PGC1α modulation could influence the metabolic fate of intestinal epithelial cells. PGC1α overexpression is not only able to stimulate mitochondrial biogenesis and metabolic activities in both colorectal cancer cells and murine intestines, it is also responsible for the accumulation of free radicals. ROS production is proportional to the increase in mitochondrial respiration and electron transport chain activity (39) . However, using muscle cells, it has been shown that PGC1α increases the expression of one of the major antioxidant enzymes of mitochondria, SOD2 (40) (41) (42) . PGC1α is therefore able to upgrade aerobic energy metabolism while preserving ROS homeostasis by promoting ROS formation on one hand and ROS scavenging systems on the other. If this is true for tissues with high aerobic energy demand, such as brain, heart, skeletal muscle, The expression of Oxphos COXI was analyzed by immunohistochemistry to highlight the mitochondrial content of normal sections of the ileum and colon from transgenic (iPGC1α) and WT mice. Intestinal activity of COX and ROS accumulation were measured on frozen ileum and colon samples from iPGC1α and WT mice. Images were quantified using ImageJ software. Apoptosis on ileum and colon from transgenic (iPGC1α) and WT mice was evaluated by TUNEL assay on paraffin-embedded samples. and brown adipose tissues (6-9, 24, 25) , in the intestine PGC1a is not able to induce the ROS scavenging systems. The intestine represents the interface between the organism and its luminal environment, being constantly challenged by diet-derived oxidants as well as by endogenously generated ROS, which can induce serious damage to all biological molecules and cell structures (43) . To preserve cellular integrity and tissue homeostasis, the intestine possesses several defense mechanisms, such as free radical scavenger enzymes CAT and SOD2. However, these antioxidant enzymes are unevenly distributed along the crypt-tovillus axis (Fig. S1B) , being poorly expressed in the villus tip and leaving enterocytes unprotected against ROS damages and cell death (15) . This uneven distribution likely renders the top of the villi and the surface epithelium weakly protected from ROS accumulation and therefore prone to regular cell turnover by apoptosis. In this study, we show that overexpression of PGC1α in tumors guarantees an increase in mitochondrial respiration and ROS production that is not linked with a sustained scavenger activity of SOD2, whose expression is actually decreased in tumors (Fig. S1B) . Thus, PGC1α in vivo produces a significant delay in tumor growth rate. On the other hand, the absence of PGC1α produces an intestinal tumor-susceptible phenotype. We therefore present an intriguing scenario whereby PGC1α is a metabolic regulator of intestinal cell fate and protects against tumorigenesis by promoting mitochondrial-mediated apoptosis via ROS accumulation.
Methods
Cell Cultures. HT29 (HTB-38), C2C12, and 143B cells were obtained from ATCC (ATCC-LGC Promochem) and were maintained in DMEM supplemented with 10% FBS and 1% penicillin/streptomycin. The generation of HT29ρ0 cells is described in SI Methods.
Mice. Nude mice for the xenograft experiments were obtained from the Jackson Laboratory. The iPGC1α transgenic mice were generated by injection into the pronuclei of the fertilized eggs of the FVB/N mice. iPGC1α Apc Min/+ mice were generated by crossing iPGC1α transgenic mice with C57BL/6-Apc Min/+ mice (Jackson Laboratory). A straight knockout strategy, deleting exons 3-5, was used to target the PGC1α locus to generate mice carrying knockout alleles at this site. Details are reported in SI Methods and in Table  S3 and Fig. S3 . The ethics committee of the Consorzio Mario Negri Sud approved this experimental set-up.
